Bioven : Your Partner in Fighting Cancer

cancer treatments

What types of cancer treatment are available today (not brand names)

Current Therapies In The Treatment Of Cancer
Typical treatments involve a combination of surgery, chemotherapy, radiotherapy, toxic drugs and more specifically targeted drugs or biological products.

Surgical removal of the tumour is performed at early stage disease progression for tumours that have not spread beyond the original site or within limited, regional boundaries. In most cancers, early detection and surgery can and does cure or delay significantly relapse of disease, e.g. surgery in earliest stage of lung cancer can lead to 10 or more year's post surgery survival.

In the case of prostate cancer, surgical removal of hormone glands is conducted to induce a hormone refractory status.

At later stages of the disease in resected and inoperable patients, different kind of therapies may be prescribed to be curative or palliative (intended to reduce pain, but not cure the disease).

The following categories are most often used alone or in combination:

Chemotherapy is the administration of drugs that stop the growth of cancer cells by killing or preventing them from dividing. This usually results in fatigue, weight loss, hair loss, nausea, vomiting, diarrhoea and mouth sores. Chemotherapy, although effective, is not specific for tumour cells and destroys other normal non-tumour cells alike.
Radiotherapy is the use of high energy X-rays or other types of radiation to kill the dividing cancer cells. In contrast to general application, radiotherapy is administered locally, targeting the physical tumour itself and leaving other tissues untouched.
Drugs ranging from general toxic substances to drugs targeting specific steps in pathways that can lead to tumour growth or drugs that target common patterns in tumour development.

Meeting Unmet Medical Needs
In late stage non-small cell lung cancer (NSCLC) and late stage prostate cancer, where chemotherapy and drug therapies have shown only modest improvements in disease-free survival, the overwhelming unmet need is for new and better tolerated treatments and protocols that extend overall survival more significantly together with prolonged good quality of life.

Bioven’s core technology is directed to actively induce antibodies to extra-cellular ligands that are relevant in cancer development pathways and has demonstrated the above in completed and ongoing clinical trials. Indeed in both lung and prostate cancer the EGF-based vaccine demonstrated significantly overall survival benefit combined with perfect tolerability, a paradigm change in oncology where most often and even marginal overall benefits are associated with severe and even life-threatening adverse events.

The Therapeutic vaccine containing EGF is the first of a kind therapeutic vaccine based on its core technology and will be followed by other candidates.